| HOME >> BIOLOGY >> TECHNOLOGY |
Other assets (28,552) (43,731)
Accounts payable and
accrued expenses 380,776 (45,820)
Other liabilities 49,465 (13,580)
Net cash provided by
operating activities 274,321 251,190
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and
equipment (70,887) (97,122)
Acquisition of intangible assets (99,152) (115,000)
Proceeds from sale of investment 12,291 -
Sales and (purchases) of
available-for-sale investments, net (43,186) 242,660
Net cash provided by (used for)
investing activities (200,934) 30,538
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of
common stock options 74,375 112,794
Windfall tax benefits from
stock-based compensation 9,934 21,912
Acquisition of treasury stock (128) (433)
Payments on and retirements of long-term
debt (2,902) (2,528)
Net cash provided by financing activities 81,279 131,745
EFFECT OF EXCHANGE RATE CHANGES ON
CASH AND CASH EQUIVALENTS 10,804 11,830
NET INCREASE IN CASH AND CASH EQUIVALENTS 165,470 425,303
CASH AND CASH EQUIVALENTS, BEGINNING
OF PERIOD 496,512 205,060
CASH AND CASH EQUIVALENTS, END OF PERIOD $661,982 $630,363
CEPHALON, INC. AND SUBSIDIARIES
Reconciliation of Proje
'/>"/>
| SOURCE Cephalon, Inc. Copyright©2007 PR Newswire. All rights reserved |